Trial Profile
A Double-Blind, Placebo Controlled, Randomized, Adaptive, First-in-Human Study to Assess, Safety, Tolerability, Pharmacokinetics and Food Effect of Single and Multiple Doses of BLU-5937 Administered Orally in Healthy Male and Female
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Camlipixant (Primary)
- Indications Cough
- Focus Adverse reactions; First in man
- Sponsors BELLUS Health
- 24 May 2023 Results from NCT03638180 , NCT03979638 and NCT04678206 evaluating the model-informed dose selection for phase 3 trials, presented at the 119th International Conference of the American Thoracic Society
- 08 Aug 2019 According to an BELLUS Health media release, data from this study was presented at the American Cough Conference on June 7, 2019.
- 21 May 2019 Results presented in a BELLUS Health media release